Format

Send to

Choose Destination
Transl Oncol. 2018 Jun;11(3):771-778. doi: 10.1016/j.tranon.2018.03.014. Epub 2018 Apr 23.

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

Author information

1
EpicentRx Inc, 4445 Eastgate Mall, Suite 200, San Diego, CA 92121, USA. Electronic address: info@epicentrx.com.
2
The George Washington University, Department of Radiation Oncology, 22nd & I Street, NW DC Level, Washington, DC 20037.
3
University of Michigan Health System, Radiation Oncology, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
4
University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.
5
EpicentRx Inc, 4445 Eastgate Mall, Suite 200, San Diego, CA 92121, USA.
6
CFLS Data, 800 West El Camino Real, Suite 180, Mountain View, CA 94040.
7
Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA.
8
InterWest Partners, 2710 Sand Hill Road #200, Menlo Park, CA 94025, USA.

Abstract

The first tenet of medicine, "primum non nocere" or "first, do no harm", is not always compatible with oncological interventions e.g., chemotherapy, targeted therapy and radiation, since they commonly result in significant toxicities. One of the more frequent and serious treatment-induced toxicities is mucositis and particularly oral mucositis (OM) described as inflammation, atrophy and breakdown of the mucosa or lining of the oral cavity. The sequelae of oral mucositis (OM), which include pain, odynodysphagia, dysgeusia, decreased oral intake and systemic infection, frequently require treatment delays, interruptions and discontinuations that not only negatively impact quality of life but also tumor control and survivorship. One potential strategy to reduce or prevent the development of mucositis, for which no effective therapies exist only best supportive empirical care measures, is the administration of agents referred to as radioprotectors and/or chemoprotectors, which are intended to differentially protect normal but not malignant tissue from cytotoxicity. This limited-scope review briefly summarizes the incidence, pathogenesis, symptoms and impact on patients of OM as well as the background and mechanisms of four clinical stage radioprotectors/chemoprotectors, amifostine, palifermin, GC4419 and RRx-001, with the proven or theoretical potential to minimize the development of mucositis particularly in the treatment of head and neck cancers.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center